A Two Part Study to Assess the Tolerability, Safety and Pharmacodynamics of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma
Latest Information Update: 21 Dec 2022
At a glance
- Drugs Nabiximols (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions; Proof of concept
- Sponsors GW Pharmaceuticals
- 24 Feb 2021 Results published in the British Journal of Cancer
- 07 Feb 2017 Top-line results published in a GW Pharmaceuticals media release.
- 10 Aug 2016 Data expected in 4Q of 2016, as per GW Pharmaceuticals media release.